American Heart Journal
Volume 152, Issue 1 , Pages 118-125 , July 2006

The impact of the ESC/ACC redefinition of myocardial infarction and new sensitive troponin assays on the frequency of acute myocardial infarction

  • Peter A. Kavsak, PhD

      Affiliations

    • Research Institute at Lakeridge Health, Oshawa, Ontario, Canada
    • Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
    • Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
    • Corresponding Author InformationReprint requests: Peter A. Kavsak, PhD, McMaster University Medical Centre, 1200 Main Street, W, HSC 2N52, Hamilton, Ontario, Canada L8N 3Z5.
    • ,
  • Andrew R. MacRae, PhD

      Affiliations

    • Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
    • ,
  • Viliam Lustig, PhD

      Affiliations

    • Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
    • ,
  • Rakesh Bhargava, MD

      Affiliations

    • Research Institute at Lakeridge Health, Oshawa, Ontario, Canada
    • ,
  • Rudy Vandersluis, MD

      Affiliations

    • Research Institute at Lakeridge Health, Oshawa, Ontario, Canada
    • ,
  • Glenn E. Palomaki, BSc

      Affiliations

    • Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
    • ,
  • Marie-Jeanne Yerna, PhD

      Affiliations

    • Immunotech S.A.S., a Beckman-Coulter Subsidiary, Marseilles, France
    • ,
  • Allan S. Jaffe, MD

      Affiliations

    • Cardiovascular Division and Division of Laboratory Medicine, Mayo Clinic, Rochester, MN

Received 19 July 2005 ,Accepted 21 September 2005.

References 

  1. Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J. 2000;21:1502–1513
  2. Alpert JS, Thygesen K, Bassand JP, et al. Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000;36:959–969
  3. Luepker RV, Apple FS, Christenson RH, et al. AHA Scientific Statement. Case definitions for acute coronary heart disease in epidemiology and clinical research studies. Circulation. 2003;108:2543–2549
  4. Jaffe AS, Ravkilde J, Roberts R, et al. It's time for a change to a troponin standard. Circulation. 2000;102:1216–1220
  5. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, et al. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation. 1994;90:583–612
  6. Venge P, Lindahl B, Wallentin L. New generation cardiac troponin I assay for the Access immunoassay system. Clin Chem. 2001;47:959–961
  7. Apple FS, Murakami MM, Pearce LA, et al. Multi-biomarker risk stratification of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death. Clin Chem. 2004;50:2279–2285
  8. Panteghini M, Pagani F, Yeo KT, et al. Evaluation of imprecision for cardiac troponin assays at low-range concentrations. Clin Chem. 2004;50:327–332
  9. Kavsak P, Lustig V, MacRae AR. Clinical evaluation of the Beckman Coulter AccuTnI assay for the early detection of acute myocardial infarction. Clin Chem. 2004;50:A5;[abstr]
  10. Brandt DR, Gates RC, Eng KK, et al. Quantifying the MB isoenzyme of creatine kinase with the Abbott “IMx” immunoassay analyzer. Clin Chem. 1990;36:375–378
  11. Agresti A, Coull BA. Approximate is better than “exact” for interval estimation of binomial proportions. Am Stat. 1998;52:119–126
  12. Armitage P, Berry G. In: Statistical methods in medical research. 3rd ed.. Oxford: Blackwell; 1994;p. 125–128
  13. Ohman EM, Armstrong PW, Christenson RH, et al. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. N Engl J Med. 1996;335:1333–1341
  14. Ferguson JL, Beckett GJ, Stoddart M, et al. Myocardial infarction redefined: the new ACC/ESC definition, based on cardiac troponin, increases the apparent incidence of infarction. Heart. 2002;88:343–347
  15. Lin JC, Apple FS, Murakami MM, et al. Rates of positive cardiac troponin I and creatine kinase MB mass among patients hospitalized for suspected acute coronary syndromes. Clin Chem. 2004;50:333–338
  16. Green GB, Beaudreau RW, Chan DW, et al. Use of troponin T and creatine kinase–MB subunit levels for risk stratification of emergency department patients with possible myocardial ischemia. Ann Emerg Med. 1998;31:19–29
  17. Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature. Circulation. 1979;59:607–609
  18. deFilippi CR, Tocchi M, Parmar RJ, et al. Cardiac troponin T in chest pain unit patients without ischemic electrocardiographic changes: angiographic correlates and long-term clinical outcomes. J Am Coll Cardiol. 2000;35:1827–1834
  19. Ottani F, Galvani M, Nicolini FA, et al. Elevated cardiac troponin levels predict the risk of adverse outcome in patients with acute coronary syndromes. Am Heart J. 2000;140:917–927
  20. Petersen JL, Mahaffey KW, Hasselblad V, et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non–ST-segment elevation acute coronary syndromes: a systematic overview. JAMA. 2004;292:89–96
  21. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet. 2002;359:189–198
  22. Sabatine MS, Morrow DA, Giugliano RP, et al. Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non–ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)–TIMI 18 trial. Circulation. 2004;109:874–880
  23. Wallentin L, Lagerqvist B, Husted S, et al. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease. Lancet. 2000;356:9–16

 This work was partially supported by funds from Beckman Coulter Inc (Chaska, MN). The generous support of the Auxiliary of Lakeridge Health Oshawa, and the Oshawa General Hospital Foundation (Ontario, Canada) is gratefully acknowledged in enabling this study.

PII: S0002-8703(05)00879-3

doi: 10.1016/j.ahj.2005.09.022

American Heart Journal
Volume 152, Issue 1 , Pages 118-125 , July 2006

Article Tools

* Image Usage & Resolution